Variable name;level;Overall;No;Yes;p;test
;n;1357;744;612;;
Age;[0 -30);95;40 (42.1);55 (57.9);<0.001;
;[30 -35);246;102 (41.5);144 (58.5);;
;[35 -40);460;240 (52.2);220 (47.8);;
;40+;554;361 (65.2);193 (34.8);;
Number of children;0;373;172 (46.2);200 (53.8);<0.001;
;1;279;153 (54.8);126 (45.2);;
;More than 1;705;419 (59.4);286 (40.6);;
BMI;<18.5;79;45 (57);34 (43);0.324;
;25-29.9;257;127 (49.6);129 (50.4);;
;>=30;107;56 (52.3);51 (47.7);;
;18.5-24.9;807;451 (55.9);356 (44.1);;
Treatment center;Curie Paris;818;421 (51.5);397 (48.5);0.002;
;Curie St Cloud;538;323 (60);215 (40);;
Hereditary predisposition;No;547;252 (46.2);294 (53.8);0.472;
;Yes;140;70 (50);70 (50);;
Inflammatory BC;No;1338;744 (55.6);594 (44.4);<0.001;
;Yes;18;0 (0);18 (100);;
Clinical Tumor size (mm);;30.3 (21.7);20.4 (16.0);42.1 (21.8);<0.001;
Clinical N stage (TNM);N0;854;540 (63.2);314 (36.8);<0.001;
;N1;482;195 (40.5);287 (59.5);;
;N2;7;0 (0);7 (100);;
;N3;3;0 (0);3 (100);;
SBR grade;Grade I;58;47 (81);11 (19);<0.001;
;Grade II;528;331 (62.7);197 (37.3);;
;Grade III;760;358 (47.1);402 (52.9);;
Histological type;Lobular;54;50 (92.6);4 (7.4);<0.001;
;NST;1265;666 (52.6);599 (47.4);;
;Others;36;27 (75);9 (25);;
Chemotherapy setting;Adjuvant;744;744 (100);0 (0);<0.001;
;Chemotherapy without surgery;1;0 (0);1 (100);;
;NAC;611;0 (0);611 (100);;
Fertility preservation discussion;No;909;543 (59.7);366 (40.3);<0.001;
;Yes;447;201 (45);246 (55);;
